Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Idola Henry Gunn

When Art Gunn asked his wife to take him to the Emergency Room on January 1, 2008, Idola was alarmed. Her husband had never had any medical problems or ever complained about being ill, so the request came as a surprise. She immediately took her husband to the Emergency Room at Andrews AFB in Maryland, where after several hours, doctors told Idola that Art might have had a blood clot.

Several hours later, Idola and Art were told that he would need to be admitted to Walter Reed Army Medical Center. Days in the Heart Ward at Walter Reed turned into a week, and Idola began to do her own research on what could be ailing her husband.

It’s still very difficult [for me] to discuss [my husband’s illness]. However, I know my husband would be proud that I’m trying to help others.

This is when Idola – after having looked into both blood clots and Art’s bone scan – first heard the words ‘prostate cancer.’ After receiving the call to return to the hospital, Art and his team of doctors informed her of his prostate cancer diagnosis: Stage IV, Grade 10. Art lost his life to the disease in 2010 at only 48 years old. Shortly thereafter, Idola found ZERO while searching for information on prostate cancer. Now she is an active advocate for the men and their partners impacted by the disease.

Determined to raise awareness, Idola attended ZERO’s Prostate Cancer Summit in early 2016, where she was a top fundraiser. She attended meetings on Capitol Hill to encourage elected officials to fund prostate cancer research at $90M.